Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer

Oncology (Switzerland)

Volumn 53, Issue 3, 1996, Pages 233-240

  Shiina, Hiroaki ^a   lgawa, Mikio ^a   Yagi, Hiroshi ^a   Urakami, Shinji ^a   Yoneda, Tatsuaki ^a   Shirakawa, Hiroki ^a   Ishibe, Tomoyuki ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Bladder; Immunohistochemistry; P53; Proliferating cell nuclear antigen; Transitional cell carcinoma

Indexed keywords

CISPLATIN; CYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CELL DIVISION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0029987891     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227566     Document Type: Article

References (25)

1. Lane DP, Benchimol S: p53 oncogene or anti-oncogenc? Genes Dev 1990;4:1-8.
2. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstcin B, Fornace AJ Jr.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-lelangicctasia, Cell 1992:71: 587-597.
3. Lane DP: guardian of the genome, Nature 1992:358:15-16.
4. Mercer WE, Shields MI, Lin D, Appella E, Ullrich SJ: Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-ccll nuclear antigen expression, Proc Natl Acad Sci USA 1991:88:1958-1962.
5. Hollslein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancers, Science 1991;253:49-53.
6. Wcmcss BA, Levine AJ, Howley PM: Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science 1990:248:76- 79.
7. Wright C, Mellon K, Johnston P, Lane DP, Harris AL, Home CW: Expression of mutant p53. c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder, Br J Cancer 1991:63: 967-970.
8. van den Berg FM, Tigges AJ, Schippcr ME, den Hartog-Jcger FCA, Kroes WG, Walbloomers JM: Expression of the nuclear oncogene p53 in colon tumours, J Pathol 1989:157:193-199.
9. Thomas DJ, Robinson MC, King P, Hasan T, Carr T, Neal DE: p53 expression and clinical outcome in prostate cancer, Br J Urol 1993:72: 778-781.
10. Tan CK, Castillo C, So AG, Downey KM: An auxiliary protein for DNA polymerase delta from fetal calf thymus, J Biol Chcm 1986:261: 1231-1236.
11. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase delta, Nature 1987:326: 515-517.
12. Mostofi FK, Sobin LH, Torloni H: Histological Typing ofUrinary Bladder Tumours, Internati-nal Classification of Tumours, No 10. World Health Organization, Geneva, 1973.
13. Karamitopoulou E, Pcrcntcs E, Diamantis I: p53 protein expression in central nervous system tumours: An immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies, Acta Ncuropathol (Berl) 1993:85: 611-616.
14. Baas IO, Mulder J-WR, Ofierhaus GJA, Vogelstein B, Hamilton SR: An evaluation of six antibodies for immunohistochcmistry of human p53 gene product in archival colorectal neoplasms, J Pathol 1994:172:5-12.
15. Vojtesek B, Barlek M, Midgley CA, Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53: New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992:151: 237-244.
16. Bacus JW, Grade U: Optical microscope system for standardized cell measurements and analyses, Appl Opt 1987;26:3280-3293.
17. Cox DR: Regression models and life tables, J R StatSoc 1972;34:248-275.
18. Moch H, Sauter G, Moore D, Mihatsch MJ, Gudat F, Waldman F: p53 and crbB-2 protein overcxpression are associated with early invasion and metastasis in bladder cancer, Virchows Arch A Pathol Anat 1993:423:329-334.
19. Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE: p53 expression, ploidy and progression in pTl transitional cell carcinoma of the bladder, Br J Urol 1993:73:533-537.
20. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhaycs I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53-gcne mutations in bladder cancers and urine samples, Science 1991; 252:706-709.
21. Lipponen PK: Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value, Int J Cancer 1993:53: 365-370.
22. Serth J, Kuczyk MA, Bokcnteyer C, Hervatin C, Nafe R, Tan IIK, Jonas U: p53 immunohis-tochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder, Br J Cancer 1995:71:201-205.
23. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexprcssion of p53 protein in transitional cell bladder carcinoma: A marker for disease progression, J Natl Cancer Inst 1993;85:53-59.
24. Hall PA, McKee PH, Du P, Menage H, Dover R, Lane DP: High levels of p53 protein in UV-irradiatcd normal human skin, Oncogene 1993;8:203-207.
25. Fritschc M, Haessler C, Brandner G: Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents, Oncogene 1993;8:307-318